Alethia BioTherapeutics, Inc., a biotechnology company, engages in the discovery and development of monoclonal antibody-based therapeutics focusing on the cancer-associated epithelial-to-mesenchymal transition, ovarian cancer, and on cancer-induced bone loss. Its products include Isogranulatimide, a G2 checkpoint inhibitor, which potentiates the response to several DNA-damaging chemotherapeutic agents; sCLU, a heterodimeric disulphide-linked glycoprotein of 449 amino acids, the over-expression of which is observed in various malignancies, including prostate, bladder, kidney, breast, colon, and lung tumors; AB-0447, an antigen that is expressed at the surface of ovarian cancer epithelial cells in greater than eighty five percent of malignant tumors; and AB-0440, a cell-surface protease-like protein, whose expression is stimulated early in osteoclast differentiation in response to RANK ligand. The company was founded in 2002 and is based in Montreal, Canada.
Current Team (9)Update
President and CEO
Executive Vice-President and Chief Scientific Officer
Director of Intellectual Property
Board of Directors & CFO
Chairman of Board of Directors
Chief Medical Officer
Director of Preclinical Drug Development
Scientific Advisory Board
Funding Rounds (2) - $4.7MUpdate
Board Members and Advisors (3)Update
The AgeChem Fund L.P. currently has $65 million under management and is seeking to invest in...
BDC Venture Capital is a major venture capital investor in Canada, active at every stage of the...
GO Capital is a $50 million venture capital fund intended to support young Quebec technology...
141, PrÃ©sident-Kennedy ave.
Suite SB-5100, Quebec,
Montréal, QC H2X 1Y4